OOIR: Observatory of International Research

Papers

(The TQCC of Current Opinion in Pharmacology is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-10-01 to 2024-10-01.)

Article	Citations
The molecular link between oxidative stress, insulin resistance, and type 2 diabetes: A target for new therapies against cardiovascular diseases	64
Dyslipidemia and diabetes mellitus: Role of lipoprotein species and interrelated pathways of lipid metabolism in diabetes mellitus	63
Nanotechnology in pulmonary medicine	55
Gestational diabetes: Implications for fetal growth, intervention timing, and treatment options	48
Prospects for COPD treatment	47
Targeting fibroblast-like synoviocytes in rheumatoid arthritis	45
The regulatory roles of dietary fibers on host health via gut microbiota-derived short chain fatty acids	42
Targeting B cells for inflammatory bowel disease treatment: back to the future	42
Transforming targeted cancer therapy with PROTACs: A forward-looking perspective	41
Current advances in the treatment of systemic sclerosis	41
Recent discoveries in HIV-1 reverse transcriptase inhibitors	37
Antihypertensive effect of soybean bioactive peptides: A review	36
A review of emerging neuroprotective and neuroregenerative therapies in traumatic spinal cord injury	35
Modulation of gut microbiota to overcome resistance to immune checkpoint blockade in cancer immunotherapy	35
Role of HSV-1 in Alzheimer's disease pathogenesis: A challenge for novel preventive/therapeutic strategies	34
The role of the liver in the modulation of glucose and insulin in non alcoholic fatty liver disease and type 2 diabetes	32
Role of O-linked N-acetylglucosamine (O-GlcNAc) modification of proteins in diabetic cardiovascular complications	32
Astrocytes as cellular mediators of cue reactivity in addiction	32
Glutamate receptors and metaplasticity in addiction	31
Circadian control of human cardiovascular function	30
Emerging mutations in the SARS-CoV-2 variants and their role in antibody escape to small molecule-based therapeutic resistance	29
Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope?	28
Paeoniflorin is a promising natural monomer for neurodegenerative diseases via modulation of Ca2+ and ROS homeostasis	27
N-methyl-d-aspartate receptor function in neuronal and synaptic development and signaling	27
Treatment of early rheumatoid arthritis: Methotrexate and beyond	26

Non-nucleoside reverse transcriptase inhibitors (NNRTIs): a brief overview of clinically approved drugs and combination regimens	26
Treatments for COVID-19: Lessons from 2020 and new therapeutic options	25
Exercise as a drug for glucose management and prevention in type 2 diabetes mellitus	25
Alpha1-antitrypsin deficiency: New therapies on the horizon	25
Chronotherapy of cardiac and vascular disease: timing medications to circadian rhythms to optimize treatment effects and outcomes	25
Does probiotics work for bacterial vaginosis and vulvovaginal candidiasis	25
The pleiotropic roles of autophagy in Alzheimer's disease: From pathophysiology to therapy	24
Applications of chemogenetics in non-human primates	24
Renal protection with glucagon-like peptide-1 receptor agonists	23
Photopharmacological control of cell signaling with photoswitchable lipids	23
The role of faecal microbiota transplantation in the treatment of inflammatory bowel disease	23
Role of intestinal glucose absorption in glucose tolerance	23
Circadian influence on inflammatory response during cardiovascular disease	23
Modafinil and its structural analogs as atypical dopamine uptake inhibitors and potential medications for psychostimulant use disorder	23
Intersection of immunometabolism and immunosenescence during aging	22
Effects of functional electrical stimulation on muscle health after spinal cord injury	22
Disruption of energy utilization in diabetic cardiomyopathy; a mini review	22
The changing landscape of the cystic fibrosis lung environment: From the perspective of Pseudomonas aeruginosa	21
Current state of CFTR modulators for treatment of Cystic Fibrosis	21
Rethinking the clinical management of volumetric muscle loss in patients with spinal cord injury: Synergy among nutritional supplementation, pharmacotherapy, and rehabilitation	21
Testosterone therapy for prevention and reversal of type 2 diabetes in men with low testosterone	21
Updated pharmacological effects of Lonicerae japonicae flos, with a focus on its potential efficacy on coronavirus disease–2019 (COVID-19)	21
TMEM16A (ANO1) as a therapeutic target in cystic fibrosis	21
Environmental enrichment-inspired pharmacological tools for the treatment of addiction	20
Drug-resistance in rheumatoid arthritis: the role of p53 gene mutations, ABC family transporters and personal factors	20
Adoptive cell therapy for solid tumors: Chimeric antigen receptor T cells and beyond	20
Current pharmacological intervention and development of targeting IVIG resistance in Kawasaki disease	19
New drugs in the pipeline for the treatment of inflammatory bowel diseases: what is coming?	19
The 2013–2016 Ebola virus disease outbreak in West Africa	19
MicroRNAs as mediators of drug resistance mechanisms	18
Optical control of Class A G protein-coupled receptors with photoswitchable ligands	18
Lipid deposition and metaflammation in diabetic kidney disease	17
Pharmacological modulation of GABAA receptors	17
Cost-effectiveness of therapeutic drug monitoring in inflammatory bowel disease	17
The blood pressure lowering effects of glucagon-like peptide-1 receptor agonists: A mini-review of the potential mechanisms	17
Recent advances in emerging PCOS therapies	17
Probing function in 3D neuronal cultures: A survey of 3D multielectrode array advances	17
Prospects for severe asthma treatment	17
Genetic risk scores and personalization of care in fatty liver disease	17
Stress, kisspeptin, and functional hypothalamic amenorrhea	17
The e-psychonaut drugs’ psychopharmacology	17
Immunogenicity, breakthrough infection, and underlying disease flare after SARS-CoV-2 vaccination among individuals with systemic autoimmune rheumatic diseases	17
Metabokines in the regulation of systemic energy metabolism	17
Hormonal drugs for the treatment of endometriosis	17
Non-alcoholic fatty liver disease: Current therapeutic options	17
Microbiota-gut-brain axis: A novel potential target of ketogenic diet for epilepsy	16
Lynx1 prototoxins: critical accessory proteins of neuronal nicotinic acetylcholine receptors	16
Elexacaftor–tezacaftor–ivacaftor: The new paradigm to treat people with cystic fibrosis with at least one p.Phe508del mutation	16
Ubiquitin proteasome system in immune regulation and therapeutics	16
RNAi therapeutics: an antiviral strategy for human infections	16

Muscle multiorgan crosstalk with MG53 as a myokine for tissue repair and regeneration	16
Pharmacologic approaches to prevent skeletal muscle atrophy after spinal cord injury	16
Three-dimensional culture models to study glioblastoma — current trends and future perspectives	15
Targeting cellular senescence as a novel treatment for osteoarthritis	15
The hypodopaminergic state ten years after: transcranial magnetic stimulation as a tool to test the dopamine hypothesis of drug addiction	15
Tackling inflammation in atherosclerosis: Are we there yet and what lies beyond?	15
Evolving understanding of cardiovascular protection by SGLT2 inhibitors: focus on renal protection, myocardial effects, uric acid, and magnesium balance	15
Pharmacology of pannexin channels	14
Targeting drug memory reconsolidation: a neural analysis	14
Recent insights into astrocytes as therapeutic targets for demyelinating diseases	14
Immune dysfunction after spinal cord injury – A review of autonomic and neuroendocrine mechanisms	14
Targeting PKC in microglia to promote remyelination and repair in the CNS	14
Recent developments and strategies of Ebola virus vaccines	14
Targeting cellular senescence as a new approach to chronic obstructive pulmonary disease therapy	13
Old and new biomarkers for volumetric muscle loss	13
Molecular routes to sarcopenia and biomarker development: per aspera ad astra	13
Design strategies for long-acting anti-HIV pharmaceuticals	13
Nutraceuticals use and type 2 diabetes mellitus	13
Overview of CF lung pathophysiology	13
Therapeutics development for Ebola virus disease: A recent scenario	13
Promising therapeutic approaches in pulmonary arterial hypertension	13
Contribution of the bone marrow stromal cells in mediating drug resistance in hematopoietic tumors	13
Role of metformin and other metabolic drugs in the prevention and therapy of endocrine-related cancers	13
Highland mate: Edible and functional foods in traditional medicine for the prevention and treatment of hypoxia-related symptoms	13
Emerging strategies for treating gout	13
Smad-dependent pathways in the infarcted and failing heart	13
Role of fibro-adipogenic progenitor cells in muscle atrophy and musculoskeletal diseases	13
Reactive oxygen species modulators in pulmonary medicine	13
Current pharmacological treatment of hepatocellular carcinoma	13
Potential mechanisms of macular degeneration protection by fatty fish consumption	13